Alitair Pharmaceuticals

Alitair is a specialty pharmaceutical company focused on respiratory space. Currently, we are developing two orphan drugs for bronchiectasis. We anticipate initiating Phase II clinical trials for these two compounds within the next six months. We are also developing products for both prescription and over-the-counter cough treatments. Our lead cough candidate is a solid oral dosage form of benzonatate, which is protected by a composition of matter patent. At present, Alitair owns four issued patents, and we expect to expand our patent portfolio in the near future.